MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

United Therapeutics Corp

Închisă

SectorSănătate

306.66 -1.76

Rezumat

Modificarea prețului

24h

Curent

Minim

297.87

Maxim

312.24

Indicatori cheie

By Trading Economics

Venit

-7.8M

301M

Vânzări

-13M

736M

P/E

Medie Sector

12.506

63.778

EPS

6.19

Marjă de profit

40.943

Angajați

1,305

EBITDA

6.3M

424M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+23.18% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.7B

14B

Deschiderea anterioară

308.42

Închiderea anterioară

306.66

Sentimentul știrilor

By Acuity

7%

93%

3 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

United Therapeutics Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 oct. 2024, 15:14 UTC

Principalele dinamici ale pieței

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparație

Modificare preț

United Therapeutics Corp Așteptări

Obiectiv de preț

By TipRanks

23.18% sus

Prognoză pe 12 luni

Medie 384.64 USD  23.18%

Maxim 460 USD

Minim 293 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUnited Therapeutics Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

8

Cumpărare

3

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

307.64 / 312.61Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

3 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.